Evidence map›Paper›PMID 40788303›Full record

ReviewNanomedicine (London, England)2025

Mechanism and applications of magnetoelectric nanoparticles in cancer therapy.

Max Shotbolt, John Bryant, Ping Liang, Sakhrat Khizroev

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Max ShotboltDepartment of Electrical Engineering, University of Miami, Coral Gables, FL, USA.
John BryantDepartment of Electrical Engineering, University of Miami, Coral Gables, FL, USA.
Ping LiangDepartment of Electrical Engineering, Cellular Nanomed, Irvine, CA, USA.
Sakhrat KhizroevDepartment of Electrical Engineering, University of Miami, Coral Gables, FL, USA.

Funding

National Science Foundation (NSF)
6 · The paper itself

Abstract

Cancer remains a major clinical challenge, with current therapies often hampered by off-target effects, drug resistance, and incomplete tumor eradication. There is a pressing need for more precise and effective treatment strategies. This review explores the mechanisms and applications of magnetoelectric nanoparticles (MENPs) in cancer therapy. MENPs, typically composed of magnetostrictive and piezoelectric materials in a core-shell structure, generate electric fields in response to magnetic fields, enabling targeted and noninvasive therapeutic actions. The literature search included recent advances in MENP synthesis, optimization of material composition and morphology, and preclinical studies demonstrating their ability to enhance drug delivery, disrupt tumor cell membranes, and induce tumor regression without systemic toxicity. Relevant studies were identified by searching electronic databases, including PubMed, Web of Science, Scopus, and Google Scholar. The search employed a combination of keywords and phrases such as "magnetoelectric nanoparticles," "MENPs," "cancer therapy," "nanomedicine," "core-shell nanoparticles," "magnetostrictive," "piezoelectric," "drug delivery," "magnetic field," "nano-electroporation," and "reactive oxygen species.." MENPs represent a promising option for precision oncology, offering remote control over therapeutic effects and the potential to overcome limitations of conventional treatments. Ongoing research should focus on optimizing MENP design for selectivity and efficacy, as well as advancing their clinical translation for cancer therapy.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsAnimalsDrug Delivery SystemsHumansMagnetic FieldsNanomedicineAntineoplastic Agentscancer therapydrug deliverymagnetic fieldMagnetoelectric nanoparticlesnanomedicine

Identifiers

PMID40788303
PMCPMC12490411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.